Advancell researches a drug for treating the most frequent chemotherapy disorders Blog Post

The biotech company – specialized in nanomedicine and cell methods for in vitro research, and located at the Barcelona Science Park- has signed an agreement with the company Nobera Pharma for the development of a drug aimed at treating palmar-plantar erythrodysesthesia, also known as the hand-foot syndrome, a very frequent side effect in cancer patients which leads to the reduction and even interruption of chemotherapy, decreasing possibilities for survival.

Advancell develops a new method for transporting live cells Blog Post

The biotech firm , located in the Barcelona Science Park, has developed an exclusive method for transporting live cells destined for research, which has a number of advantages over existing methods. The equipment necessary for maintaining cell viability comes in kit form, and works at room temperature. The idea, which has been patented by the company, may help provide a way into new markets and contribute to the development of new cell kits in conjunction with other firms.

Bosch i Gimpera-UB Foundation to run 2nd CREA!EMPRESA training day Blog Post

On Wednesday 26 November the Barcelona Science Park (PCB) will host the second CREA!EMPRESA training day. Organised by the Bosch i Gimpera Foundation the aim is to encourage the creation of technology-based companies in the university community. Registration is free and the meeting runs from 12 to 3.00 p.m. in the Fèlix Serratosa Room of the Modular Building (Baldiri i Reixac, 10).

Advancell joins European Project to Regulate Use of Nanoparticles Blog Post

The biotech firm , housed at the Barcelona Science Park, is the only company that will be taking part in the European , project sponsored by the European Commission. The aim of the project is to develop a methodology for the systematic assessment of the potential toxicity and other health effects of nanoparticles in order to help in future drafting of specific regulations covering their use.

Advancell secures funding of 11 million euro to boost its projects Blog Post

The biotechnology company , based in the Barcelona Science Park, has announced that it has secured funding of 11 million euro to boost the majority of its most immediate projects. The deal is based on a capital increase of 7.5 million euro from private sources and the award of 3.5 million euro in loans from public or semi-public bodies, including the Centre for the Development of Industrial Technology (CDTI) and the Ministry of Education and Science. The 7.5 million euro corresponding to increased capital has mostly come from Advancell shareholders.

Advancell and Protherics begin the co-development of a new drug for the treatment of a kind of leukaemia Blog Post

, a company focused on biotech research, and , a British enterprise specialized in the development and marketing of innovative pharmaceutical drugs for oncological treatments and of drugs used in critical care, have launched a project to develop the Acadesine molecule for the treatment of beta-cell chronic lymphocytic leukaemia (B-CLL), a disease that affects about 300,000 people worldwide. The clinical development of this molecule could imply an investment of more than 50 million euros.